1 asset in Non-Functional Pancreatic Neuroendocrine Tumor

Therapeutic assets addressing Non-Functional Pancreatic Neuroendocrine Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Non-Functional Pancreatic Neuroendocrine Tumor	National Cancer Institute (NCI)	P3	NR ()